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Abstract: After injury to the spinal cord, edema contributes to the underlying detrimental
pathophysiological outcomes that lead to worsening of function. Several related membrane proteins
called aquaporins (AQPs) regulate water movement in fluid transporting tissues including the
spinal cord. Within the cord, AQP1, 4 and 9 contribute to spinal cord injury (SCI)-induced edema.
AQP1, 4 and 9 are expressed in a variety of cells including astrocytes, neurons, ependymal cells,
and endothelial cells. This review discusses some of the recent findings of the involvement of AQP
in SCI and highlights the need for further study of these proteins to develop effective therapies to
counteract the negative effects of SCI-induced edema.
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1. Introduction–Human Aquaporins
Water can move rapidly into and out of most cells of the human body. This passive, bidirectional
transport of water may occur directly across biological membranes. However, the phosopholipid
bilayer can restrict the rate of water flow depending on the properties of the cell [1]. As such, the rate
of water transport can be increased through co-transport with other solutes and/or ions such as
salt [2] or through water channel proteins. This type of transport is important for the maintenance
of physiological homeostasis and it seems that the majority of rapid water transport occurs through
aquaporins (AQPs) [3]. AQPs are a family of transmembrane (TM) channel proteins that facilitate the
transcellular flow of water through biological membranes in response to changes in osmotic and/or
hydrostatic pressure [4,5]. Thirteen functional human AQP isoforms have been discovered to date
with ubiquitous yet differential expression across tissues of the human body [6–8].
The initial discovery that AQPs were functional water channels came from transiently transfecting
AQP1 into Xenopus oocytes which, when exposed to distilled water, swelled significantly when
compared with control, non-transfected oocytes. This was the result of increased AQP1 levels
present within the cell membrane, which allow an influx of water to occur when the extracellular
solution was hypotonic to the intracellular [9,10]. The discovery of AQPs and the development of
such models has advanced our understanding of how cells and tissues regulate water flow under
physiological and pathological conditions. The involvement of AQPs in many pathologies has since
been increasingly brought to fruition including in cancer, epilepsy, and neurodegenerative diseases.
As such, our understanding of AQPs, not only as passive facilitators of water flow but as mediators of
pathological conditions, is crucial for increasing potential therapeutic targets among clinical treatments.
Researchers seek to undersand more about how AQPs contribute as therapeutic targets, how they are
regulated, and how we may intervene.
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1.1. Structure of Mammalian AQPs
AQPs appear to exist functionally in a common homotetrameric structure [5] with recent evidence
suggesting that each of the monomers behave as a functional water transport unit (Figure 1) [11].
The role of tetramerization is still incompletely defined. However, recent evidence suggests it is a
requisite of the regulatory mechanism [12]. Like most TM transporters, AQPs have evolved to become
highly specific for their transport molecules. AQP monomer structures exist in an “hour-glass”
3D conformation consisting of a hollow but constricted “pore” formed of six transmembrane
α-helices [13,14]. The most constricted region of this pore is approximately 2.8 Å in size, which allows
the continuous passage of one water molecule at a time. This is known as a single file permeation [15,16].
The electrostatic factors controlling single file permeation are conferred by the hydrophilic residues
lining each pore. This includes a tightly constricted region towards the extracellular side of the pore
containing an aromatic/arginine (ar/R) motif and two α-helices, which repel the passage of protons
and define exquisite specificity for water molecules, and two Asn-Pro-Ala (NPA) motifs within the
highly conserved pore-forming B and E loops, which interact in the center of the protein and form
hydrogen bonds with water molecules to facilitate transport into the intracellular compartment of
the AQP (Figure 1) [17–19]. These features allow AQP monomers to facilitate effective capacity and
selectivity for water transport including allowing up to 3 × 109 molecules of water per second across
in some water-selective AQPs, e.g., AQP1, 2, 4 and 5 [4,20].
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Figure 1. The secondary, tertiary, and quaternary str ctures of Aquaporin proteins. (A) The secondary
structure of aquaporins contains six a-helices connected by three extracellular and two intracellular
loops. Loops B and E contain NPA motifs and the fifth a-helices contain ar/R motifs, which is described
in the text. (B) All six α-helices exist in a closely associated tertiary mo omer structure with both
ar/R motifs interacting at opposite sides of the pore and oth NPA otifs interacti g within the
membrane. The route of water passage exists in the transmembrane pore formed through the center of
the three-dimensional barrel. (C) AQP monomers homotetermerize and create a five-pore quaternary
structure. However, the function of the central pore, formed by the space between all four monomers,
remains largely unknown.
The tertiary structure of AQPs is considered to be of an hourglass shape with the α-helices tilting
to form a barrel (Figure 1) [21]. Furthermore, subangstrom resolution-scale studies using molecular
dynamics have revealed that water moves through the selectivity filter in a choreographed, pair-wise
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manner, which maintains electrical favorability and allows rapid transport of water through the
channel [18]. Additionally, some AQPs termed ‘aquaglyceroporins’ also have selectivity for small
polar molecules such as glycerol and urea [22]. These AQPs, namely AQP3, 7, 9 and 10, have an altered
architecture and polarity within the constricted region that can accommodate transport of these larger
molecules [22,23]. As such, the pore is slightly larger at approximately 3.8 Å and is lined with more
hydrophobic residues to accommodate interactions with the additional cargo [14,24].
1.2. Localization and Functions of Human AQPs
There are 13 functional isoforms of human AQPs currently identified with each containing
specific and localized expression patterns and functions. These isoforms have subtle differences in
the primary, secondary, and tertiary structures of the proteins. The most important differences are
those observed within the elements that line the pore of the channel especially the residues that offer
capacitance or resistance to water and sometimes other small molecules. Since different tissues in the
body require transport at different rates, the isoform localization of AQPs reflects this specificity of
action. For example, different cell types in the kidney collectively express nearly all known human
AQPs (AQPs 1–4 and 6–11) while the spleen only appears to express AQP9 [25]. AQPs serve different
physiological functions within the body depending on their localization and isoform. Arguably the
most important function of AQPs is to facilitate the general maintenance of water homeostasis within
tissues [26]. This is achieved mostly though cell volume regulation (CVR) mechanisms and ensures that
the osmolarity within the cell is maintained within a physiological range [27,28]. Other, more specific
functions of aquaporins include, but are not limited to, water transport across kidney tubule epithelium
through AQP2 [29], production of sweat and saliva through AQP 5 [30], and blood-brain/blood-spinal
cord water transport through AQPs 1 and 4 [1,31].
1.3. Regulation of AQPs
Water permeation is a dynamic and fluctuating process in most tissues of the human body and,
therefore, functional regulation of AQPs are critical to their activity. This is to ensure that water flow
occurs at the appropriate locations and rates for each cell or tissue. Regulation of protein expression
is generally the most common means of protein regulation since transcriptional rates of most genes
physiologically fluctuate especially under stress [32]. This has also been demonstrated for AQPs.
Activation of protein kinase C (PKC) decreases expression of AQPs 4 and 9, which can be prevented
by the addition of PKC inhibitors. This suggests that their expression levels may be regulated by
cellular stressors or signals that are mediated through PKC [33]. Many other studies report AQP gene
expression levels being changed both via mRNA upregulation and downregulation under a wide
variety of different pathophysiological conditions such as human renal and muscular diseases as well
as after CNS trauma [34–36].
The most common and frequently observed method for regulating AQP activity is through
conformational ‘gating’. This type of regulation was first reported in plant AQPs such as those
in spinach where an intracellular loop physically barricades the intracellular pore following
dephosphorylation at a local serine residue [37,38]. While this regulatory mechanism is used extensively
by many biological membrane proteins, it’s unclear whether this also occurs as distinctly or as
frequently in the proteins of mammalian cells. This remains a controversial topic in the field. Further
to blockage gating, some studies report that AQP4 may also be gated by a physical narrowing of the
channel pore that becomes too small for water molecules to pass through. Molecular dynamics studies
reveal that a histidine residue in the cytoplasmic side of the pore may reorientate and interact with a
nearby cysteine residue, which constricts the pore [39]. However, no biological relevance of this gating
has yet been reported.
Another potential AQP regulation mechanism involves alteration of the abundance of AQPs
at the cell membrane via protein trafficking. This hypothesis postulates that enhanced water flow
may be the result of variable rates of translocation among AQP channels between the cell membrane
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and intracellular stores (short-term). Evidence for such a mechanism has been well demonstrated
for AQP2 in kidney endothelium [40]. In this context, AQP2 is thought to be under the regulation
of vasopressin-mediated translocation to the membrane of principal cells of the renal collecting duct,
whereby vasopressin binding to its natural receptor, the vasopressin type 2 receptor (V2), results in a
G-coupled intracellular response leading to protein kinase A (PKA) activation, AQP2 phosphorylation,
and the ability to translocate to the basolateral membrane [40–42]. This mechanism has also been
demonstrated to occur with AQP1 and AQP4. One study demonstrated through an oocyte cell-swelling
assay that cyclic adenosine monophosphate (cAMP)-dependent PKA phosphorylation of AQP1
resulted in increased cell swelling due to the increased abundance of functional AQP1 at the cell
surface [43]. It was suggested that this was due to direct phosphorylation of AQP1. However, the study
does not indicate whether this regulates AQP function through gating or by protein trafficking. In
contrast, a similar regulatory mechanism was also reported in AQP4. However, this showed decreased
AQP4 permeability after PKC activation and phosphorylation of Ser180 [44,45].
Mechanisms for the short-term regulation of AQPs are unclear especially any differences between
isoforms and tissues. Since water transport is determined passively by changes in osmolarity and
tonicity, the rate of this transport seems to be mostly determined by the abundance of AQPs present at
the cell membranes. Therefore, more research is needed to elucidate the exact regulatory mechanisms
controlling each of the AQPs including some of which may be tissue specific as well as altered within
disease or damage states. Regulation of CNS-localized AQPs will be discussed later in the context of
their functions.
2. AQPs in the CNS–Physiological Roles
The central nervous system (CNS), which is comprised of the brain and spinal cord, is responsible
for collating and processing neuronal information, interpreting its meaning, and, in some cases,
coordinating an appropriate response. It is comprised of a vast number of highly specialized cells,
which can be broadly categorized into neuronal cells and glial/supporting cells. These all work
in tight coordination to ensure that its functional responsibilities are efficiently fulfilled [46,47].
The functionality of the CNS is very tightly coupled to the ionic and osmotic environments within the
tissue and surrounding the tissue. The basic principles of neuronal conductivity rely on a balance of
intra-cellular and extra-cellular concentrations of Na+, K+, and Ca2+ ions, which affect intra-cellular
and extra-cellular osmolarity, and vice versa. Changes in osmolarity determine the flow of water into
both cells and the extracellular space from the blood. Furthermore, the brain exists within a finite
space, which is determined by the size of the skull. Water content within the brain directly affects
intracranial pressure, which is asserted on the tissue [48]. Water levels must be effectively regulated
to ensure that the brain volume does not become too high, which results in increased intracranial
pressure (ICP) and leads to conditions such as intracranial hypertension (IH) [49].
The potential fluid-tissue interfaces that exist for exchange in the CNS are extremely restricted
including those for water molecules. As such, to maintain the optimal osmotic environments, the CNS
must be specialized to ensure that water homeostasis is regulated efficiently to maintain optimal
functionality. One of the key specializations is the presence of specific AQPs. Transcriptional profiling
of rodent genes indicates that in the healthy, uninjured mammalian spinal cord, there is an expression
of AQPs 1, 4, 5, 8, and 9 across different cell types [50]. Some CNS AQPs are expressed most
predominantly in distinct cell types. For example, AQP4 is expressed in astrocytes or AQP5, 8 and 9 are
expressed in neurons [50–52]. These AQPs regulate water flow between intracellular and extracellular
compartments to regulate cell volume, osmolality, and ion concentration. However, their expression
levels and functions within different regions of the CNS vary and, since the blood-CNS barriers are
so tightly restricted, AQPs represent the primary mechanism of mass water transport into and out of
the CNS. Currently, only AQPs 1, 4, and 9 have been functionally implicated in the spinal cord and,
as such, our discussion will be limited to these. However, an overview of the localization and known
functions among all CNS AQPs can be found in Table 1.
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Table 1. Comparison of expression and known or suggested functions of AQPS 1, 4 and 9 in the spinal cord and brain. DRG = dorsal root ganglia, DH = dorsal horn,
CSF = cerebrospinal fluid, CPE = choroid plexus epithelia, (*) = not fully investigated.
Spinal Cord Brain
References
Location Function Location Function
AQP1
Unmyelinated sensory fibers in DRG,
DH, and grey matter Pain processing Ependymal cells in the CPE CSF production
[31,50,52–63]
Endothelial cells within glia limitans Unknown
Perivascular astrocytes in
white matter, and glial
limitans
Cell migration, water
homeostasis
Astrocytes within glia limitans, dorsal
horn, central canal and white matter
Cell migration, water
homeostasis Neurons surrounding pial
blood vessels
Axonal elongation
Ependymal cells within glia limitans and
central canal CSF production (*)
AQP4
Astrocyte end-foot processes encircling
capillaries in grey and white matter
Water homeostasis,
ionic homeostasis
Perivascular end-foot
processes in white matter
Water and waste
clearance
Neuronal excitability
[50,61,62,64–81]
Astrocyte end-foot processes enveloping
myelinated axons and axonal synapses
Regulation of
perisynaptic volume
Astrocyte processes facing glia limitans
and surrounding central canal Water homeostasis (*)
Perisynaptic astrocyte
end-foot processes
Synaptic function
Perisynaptic volume
Synapse plasticity
K+ homeostasisFibrous astrocytes Unknown
Ependymal cells within glia limitans CSF production (*),
water homeostasis (*)
Subpial and subependymal
astrocyte processes Water flow
Muller cells K+ clearance
AQP9
Astrocyte end-foot processes in white
matter and glia limitans Water flow (*)
Catacholinergic neurons Energy metabolism (*)
[50,62,82,83]
Astrocytes in glia limitans Water flow (*)
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2.1. AQP1
AQP1 expression has been reported at locations throughout the entire CNS in multiple cell
types including ependymal cells, astrocytes, and, to a lesser degree, vascular endothelial cells [52–54].
The most abundant expression of AQP1 is at the apical membrane of choroid plexus epithelium
(CPE) ependymal cells in the brain–the tissue residing in the lateral, third, and fourth brain ventricles,
which is responsible for the production of cerebrospinal fluid (CSF) [55,56,84]. It is the role of AQP1 to
facilitate rapid and regulated water transport between the CPE and the ventricles in order to produce
CSF. When AQP1 is knocked down in mice, there is an 80% reduction in the water permeability of the
luminal CPE membrane but only a 25% reduction in CSF production [31]. This suggests two things.
First, despite the passive nature of AQPs, their expression levels should not be interpreted directly as
being representative of absolute water flow. This is because AQPs do not actively control water flow.
This remains under the control of the local osmotic pressures they are exposed to. Second, there may
be other non-AQP1-dependent mechanisms facilitating CSF production in the CFE potentially via
paracellular transport. CSF release through AQP1 is thought to be very important for maintaining
physiological ICP since AQP1 knockout mice exhibit 56% lower ICP than controls [31].
In addition to ependymal cells, a small population of AQP1 appears to be expressed within
some neuronal and glial cells in the brain. Immunolocalization studies evaluating the expression
changes of AQPs following the CNS insult have revealed that, even in sham controls, a small level
of AQP1 expression may be observed within the rat parietal cortex. While the precise physiological
role of AQP1 in these neurons remains unknown, evidence suggests that their upregulation in
traumatic brain injury (TBI) models is involved in pain processing and, therefore, perhaps their
role is more pathological [57,85]. Furthermore, while AQP1 is not detected in astrocytes in the healthy
brain, it appears to be upregulated within astrocytomas in humans [58,59] and also in astrocytes
following a subarachnoid haemmorage and following brain stab injury in rats [60], which is an effect
that has been shown by cell culture studies to probably occur in response to hypertonicity via a
hypertonicity-response element in the AQP1 gene [86,87].
2.2. AQP4
AQP4 is expressed in high levels across the brain, spinal cord, and retina as well as in some
peripheral nervous tissue with the highest expression levels detected in the cerebellum and spinal cord
grey matter [50,64]. Furthermore, its expression has been localized in multiple cell types including
astrocytes, endothelial cells, and some smaller populations of neurons [50,65]. Its functions are thought
to include aiding astrocyte signalling, regulation of local ion homeostasis, and CVR (cell volume
regulation) [88,89].
2.2.1. Astrocytes
The most prominent location of AQP4 in the CNS is within the membranes of polarized
astrocyte perivascular end feet surrounding blood-CNS and CSF-CNS interfaces in the brain and
spinal cord (Figure 2) [65,67]. Accordingly, AQP4 expression strongly co-localizes at this site
with glial markers such as glial glutamate transporter-1 (GLT-1) and glial fibrillary acidic protein
(GFAP) [68]. AQP4 becomes confined to endfeet membranes due to the interaction of this membrane
region with other cell types. The relative level of immunoreactivity of AQP4 in the membrane
compartment of astrocytes significantly increases in the presence of agrin, which is a membrane-bound
proteoglycan found on neurons and endothelial cells [90,91]. Furthermore, α-syntrophin knock-out
mice display significantly reduced endfeet-localized AQP4 than wildtype controls, which is supported
by other studies demonstrating that astrocytes co-cultured with endothelial cells also decrease their
membrane-to-cytosol AQP4 expression when α-syntrophin is knocked down [92,93]. AQP4-expressing
astrocyte endfeet can be found throughout many locations of the CNS with the highest abundance
surrounding the blood vessels within the superficial laminae of grey matter in the spinal cord and at
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the pial membranes at the surface of the brain. AQP4 is also found to a lesser degree in astrocyte end
feet surrounding the glial-limiting membrane, myelinated neuronal fibers, and the central canal of the
spinal cord [50,61].
The identification of AQP4 at these locations probably relates to the identification of crystal-like
intramembranous protein ‘assemblies’ that were previously observed in the brain and termed
orthogonal arrays of particles (OAPs) [66,69]. AQP4 was subsequently confirmed as the OAP protein
constituent due to their disappearance in Aqp4−/− knockout mice [70]. These AQP4 assemblies are
built from M1 and M23 isoforms of the protein monomer and the relative abundance of these isoforms
directly affects the polarization of AQPs to astrocytic endfeet [71]. Higher M23:M1 ratios favor larger
OAP formations, which increases the water permeability of the endfeet [94]. Collectively, the tissue
and subcellular localization of AQP4 in the CNS alludes to the primary functions of AQPs in the
CNS. For example, the strong expression of AQP4 around the brain and the spinal cord astrocyte-fluid
interfaces strongly suggests that AQP4 has an important role in regulating water flow into, and out of,
the CNS.
Many of the physiological functions of AQP4 have been revealed by using genetically modified
mice models exposed to varied pathological conditions [72]. One of the earliest examples of this was
in Aqp4−/− mice models, which exhibited vastly reduced levels of post-ischemic edema following an
induced ischemic stroke [73]. Furthermore, AQP4 deletion within glial cells in mice resulted in a 31%
decreased uptake of water into the brain following hypo-osmotic stress. However, the overall brain
dry mass did not change, which suggests that the role of AQP4 at the blood-brain (and potentially
blood-spinal cord) barriers exists pathophysiologically and mediates water absorption in hypo-osmotic
conditions [74]. More specifically, AQP4 has been demonstrated to regulate cell volume homeostasis
by maintaining extracellular solute clearance. For example, primary astrocytes demonstrate a response
to hypo-osmotic stress by rapidly increasing cell volume, which is a response that was absent from
identical mouse astrocytes in which AQP4 is knocked down (Aqp4−/−) [75]. Additionally, AQP4 is
also expressed at other astrocytic locations including perisynaptically but to a significantly lower
density [65]. It is documented that high-frequency activation of excitatory synapses results in a
reduction in the extracellular space surrounding the synapse [76]. However, in Aqp4−/− mice,
this volume reduction is enhanced [74]. Therefore, AQP4 is thought to regulate perisynaptic volume by
increasing water efflux in response to hyperosmolality, which occurs due to high-frequency activity and
the resulting water absorption through the Na+/K+/2Cl− cotransporter 1 (NKCC1) into astrocytes.
AQP4 is also present with a non-polarized distribution within fibrous astrocytes of the spinal cord
white matter and optic nerve and also within Muller cells within the retina [61,77,95]. In the spinal
cord, white matter astrocytes expressing AQP4 are present throughout the whole of the membrane
including along processes and at the cell body. These processes extend radially across the white matter
regions—from borders of grey matter to the outer glial limitans [78]. More specifically, these processes
have been found to envelope myelinated neuronal fibers [61]. However, the physiological and
pathophysiological relevance of AQP at this localization remains currently unknown.
Most of the studies investigating roles of astrocytic AQP4 tends to focus on either the brain or the
spinal cord. At present, the translation of knowledge of the AQP4 location to physiological function
is not conclusive. However, due to the highly similar cellular and sub-cellular distribution seen at
different CNS locations, it is expected that the same or similar functional mechanisms of AQP4 occur
throughout the whole CNS.
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2.2.2. Ependymal Cells
AQP4 is also observed within the basolateral membrane of the ependymal cells surrounding
brain-CSF barriers [66]. This suggests that AQP4 has a physiological function in maintaining water
transport between CSF and CNS parenchyma. Some studies suggest that ependymal AQP4 is involved
in transependymal CSF flow and/or reabsorption, which, when disrupted as in Aqp4−/− mice, results in
sporadic hydrocephalus [79]. However, more research is required to clarify the role. Ependymal AQP4
expression has been notably observed in the medial habenula (HB) of the brain, which is a region
involved in many cognitive processes such as mood and anxiety regulation [64,96].
2.3. AQP9
In the normal spinal cord, AQP9 is expressed in astrocytes, catecholaminergic neurons,
and endothelial cells of sub-pial blood vessels [50,62,82,83]. AQP9 is localized to the plasma membrane
and facilitates the flow of water, glycerol, monocarboxylates, and urea.
3. Spinal Cord Injury and Oedema
A spinal cord injury (SCI) can be broadly categorized into being of traumatic or non-traumatic
origin. The former is the result of external physical insult (for example, a car accident) and the
latter is the result of a much more diverse range of internal insults (for example, a tumor) [97].
The incidence of SCI is not easily defined probably due to the highly varied nature of the condition and
the complications with a guaranteed diagnosis. A recent world-wide review of the literature reporting
SCI incidence rates suggests that, in developed countries, the rates range between 13.1 to 163.4 per
million incidents of SCI and, in non-developed countries, the rates range between 13.0 to 220.0 per
million [98]. According to the World Health Organization (WHO), patients suffering from SCI have
a much higher incidence of depression compared to the overall population estimates and are up to
five times more likely to die prematurely [99,100]. Furthermore, SCI has a significant economic impact
both on the individual and on the society with economic consequences on top of the costs of personal
care [99,101,102]. As such, research is absolutely vital to investigate how spinal cord injuries manifest
with such devastating functional consequences and vital for creating interventions that can minimize
damage and subsequently ease the socioeconomic burden of SCI.
Edema is a clinically important feature in the progression of SCI that causes secondary damage
through physical contortion and/or obstruction of nerve fibers and vasculature that were, otherwise,
uninjured by the primary damage [103]. Shortly following injury to the human spinal cord, there is
a significant increase in the amount of water accumulating in the parenchyma of the damaged
region [104]. This water, termed ‘edema’ forms within the acute phase of secondary injury pathogenesis
and may persist for weeks. It is a vital element of SCI pathology since some studies report that the
severity of the edema (generally the size and location of the swelling) is strongly correlated to the
clinical outcome especially in terms of motor recovery [104,105]. Evidence shows that the edema
formation begins within minutes from the epicenter of the primary injury and develops outward
into a larger fluid-filled cavity within 48 hours and may persist for up to 14 days post-injury [106].
While the exact molecular mechanisms facilitating edema formation are not clear, it is thought to be a
consequence of both the swelling of neurons and astrocyte end-feet (cytotoxic edema) coupled with
the disruption and leakage of the blood-spinal cord barrier (BSCB) (vasogenic edema).
Cytotoxic edema is more prominent in astrocytes than in neurons due to their sensitivity to
K+ levels for clearance [107]. It happens as a response to a combination of local inflammatory
mediators, ATP deprivation, and the local release of arachidonic acid produced via membrane
lipid metabolism [108,109]. Collectively, these factors influence dysfunction of ATP-dependent
Na+ K+-ATPase pumps, which drive excess Na+ down its electrochemical gradient and cause ionic
imbalance [108,110]. To counter this, an excess of Cl− ions is then driven into the cell to electrically
neutralize it, which is followed by the influx of water into astrocyte endfeet. This results in cell
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swelling [111]. AQP4 is considered to be the mediator of this pathogenic water influx (which will be
discussed later).
Cytotoxic edema creates a premorbid driving force leading to ionic oedema, which is a
process whereby highly concentrated extracellular ions (e.g., Na+) are altered in their normal
concentration gradients. This secondarily affects the driving force for secondary molecules (e.g., Cl−).
This dysregulation then modulates the transendothelial concentration of Na+ where the blood
concentration of Na+ is significantly higher than that of the parenchymal concentration, which creates
a new Na+ gradient and causes a water flux into the parenchyma across the intact BBB. This is the
first stage of CNS tissue swelling [112]. The relative osmotic imbalance across the blood-CNS barrier
then creates a gradient whereby water flux favoring the parenchyma occurs and the capillaries (and
potentially larger vessels) now behave as though fenestrated, aiding the formation of permeability
pores and resulting in vasogenic edema.
Vasogenic edema describes the disruption of BSCB integrity where molecules that are normally
highly restricted in their passage across this barrier can pass more freely such as water, glucose,
and some plasma proteins. It may be observed as quickly as 90 s following the primary injury and
can persist as late as two weeks in rat models [113,114]. Collectively, cytotoxic and vasogenic oedema
are both critical and associated processes. Even though cytotoxic edema alone may not necessarily
produce mechanical or pressure-induced impact to the spinal cord, it may intensify the premorbid
state of the tissue and favor the formation of vasogenic edema.
Edema causes exacerbation of the primary injury by raising intrathecal pressure within the spinal
cord, which causes further damage by reducing blood flow, leads to hemorrhages, BSCB disruption,
and, subsequently, further cell death [115]. However, since edema is often a quick-onset and
long-lasting feature of SCI, it remains somewhat resistant to interventions, which makes it a great
challenge to overcome or prevent clinically. As such, understanding the causes and molecular
mechanisms involved in the formation of edema after acute SCI is important for developing ways of
attenuating its development in order to improve or abolish the adverse clinical outcomes resulting
from secondary damage.
The mechanisms of edema formation in SCIs are associated with dysregulation of water transport,
which leads to the swelling of astrocyte end feet and the formation of fluid-filled cavities. This indicates
that water homeostasis and the proteins involved in water transport may contribute to the resulting
pathologies and, as such, may offer themselves as therapeutic targets to prevent the secondary damage
elicited from edema. The exact role of AQPs in edema pathogenesis remains controversial due to
published studies reporting conflicting results about the role of AQPs in causing and resolving different
types of edema [82,116–121]. It is clear that AQPs play important roles in both phases of edema in the
spinal cord and further studies are required to investigate the exact mechanisms associated with AQPs
and their contribution to both of these processes. Herein, we will discuss the available information on
AQP and their role in water regulation after SCI.
3.1. AQP1 in SCI
AQP1 levels have been shown to significantly increase under a broad range of neuropathological
conditions such as Alzheimer’s, Creutzfeldt-Jakob disease, traumatic brain injury (TBI),
and SCI [63,122–124]. In uninjured spinal cords, AQP1 expression is predominantly localized to
neuronal fibers and ependymal cells. Following SCI, not only did expression increase in these
cells, but also in astrocytic cell bodies and with elevated levels persisting for up to 11 months
post-injury [124]. This persistent and multicellular localization suggests the possibility that AQP1
contributes to different pathological processes after SCI. Extracellular hypertonicity did not affect
AQP1 unlike AQP4 that increases robustly as a result of hypertonicity. However, oxidative stress
significantly increased AQP1 protein expression while the antioxidant melatonin suppressed this
AQP1 upregulation [124]. Since AQP1 is expressed after hypoxia in endothelial cells play a role in
angiogenesis and cell migration [116,125], AQP1 was postulated to have a similar function in astrocytes
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of the spinal cord or in axon elongation via water uptake [124]. In support of this assertion, AQP1 was
found colocalized with the axonal growth marker GAP43. However, such sustained and persistent
upregulation of AQP1 may enhance neuronal/axonal swelling [117] and may result in overproduction
of CSF by ependymal cells or fluid-filled cysts after SCI [36,124]. Upregulation of AQP1 after SCI was
found in reactive astrocytes surrounding the lesion site and, although the role of this response is not
clear, it suggests that AQP1 may facilitate astrocyte migration to the lesion site.
3.2. AQP4 in SCI
AQP4 is the most well-characterized AQP after SCI. AQP4 protein levels appear to change
biphasically after SCI, starting with an immediate decrease between onset and three days post-injury,
which is followed by a significant increase seen as late as nine months post-injury [36]. In ischemic
stroke models, Aqp4−/− mice exhibited 35% less cerebral edema when compared to wild-types (WT)
with significantly reduced astrocyte endfoot swelling [73]. Further studies investigating SCI have also
yielded similar conclusions whereby the inflammatory mediator IL-6 induces a HMGB1-mediated
signaling cascade resulting in the increased expression of AQP4 in astrocyte endfeet and a subsequent
increase in cytotoxic swelling [118]. In Aqp4−/− mice, there is also reported functional and pathological
improvement after compression SCI in which mice demonstrated significantly higher motor scores
and decreased edema than their WT counterparts for up to 14 days post-injury [119].
Collectively, studies focused on the roles of AQP4 in cytotoxic edema suggest that AQP4 is a
mediator in the formation of cytotoxic edema in the CNS. However, more recently, a study showed that
inhibition of AQP4 by TNG-020, which is a direct AQP4 inhibitor, following SCI reduces spinal cord
water content and AQP4 expression cumulatively with the dose of the inhibitor [80]. This suggests that
AQP4 also has a role in the formation of water accumulation involved in vasogenic edema. However,
the precise mechanistic link has not yet been identified. In contrast, other studies focused on vasogenic
edema, which resulted from BBB/BSCB dysfunction, demonstrating that AQP4 is crucial for facilitating
the clearance of water [81].
In Aqp4−/− mice, it was observed that vasogenic edema, as determined by water content,
was significantly higher up to 28 days after compression SCI when compared to control levels,
which was not observed in the wild-type (WT). Furthermore, these Aqp4−/− mice also appeared
to have a poorer functional recovery following SCI than their WT counterparts [120]. Another study
showed that when Aqp4−/− mice were subject to transectional SCI, the water content within the injured
half of the spinal cord was significantly higher than the water content within the uninjured half of the
spinal cord in Aqp4+/+ mice three days post-surgery. This suggests that knockdown of AQP4 enhances
edema even in acute stages of SCI pathogenesis [121].
It is important to consolidate and resolve the differences observed for the roles of AQP4 between
cytotoxic and vasogenic edema since both of these elements have been demonstrated to occur following
human traumatic SCI [113,126]. Despite the fact that cytotoxic edema itself is not thought to cause
the physical contusion that results in secondary injury, it is thought to be the ionic driving force that
leads to vasogenic edema and the build-up of fluid-filled cavities that cause secondary damage [127].
As such, the traditional categorization of edema into “cytotoxic” and “vasogenic” is being increasingly
considered as an oversimplification of the two sides of a connected process.
The conflicting evidence also suggests that, in addition to the role of AQP4 in different types of
edema, there must also be consideration about the type of the experimental model used since different
models reflect different types of human SCI including both the severity and the pathophysiological
processes that occur. For example, transactional laceration SCI likely results in significantly larger
amounts of vasogenic oedema due to the direct compromise of BSCB while contusion SCIs likely spare
the BSCB directly, which implies that they occur through different processes [128,129]. Furthermore,
there is a time element to be considered, since Aqp4−/− mice examined shortly after injury appear to
have reduced edema and better behavioral functionality than those examined later. This suggests
that the role of AQP4 following SCI may be biphasic, having an edema-forming role immediately
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following injury, followed by a resolution role in later stages. Perhaps this functionally biphasic
phenomenon of AQP4 is a result of it having two different roles. The pathological role of causing
edema by encouraging cytotoxic and/or vasogenic oedema is followed by the physiological role of
maintaining ionic homeostasis by regulating water flow.
There is a need for clarification between the differences in the role of AQP4 in different
types/stages of edema formation and resolution in different models of SCI and over the extended
time-course after injury (Figure 3). Such information would also require an understanding about the
impact of the severity of the injury on the role of AQP4. Furthermore, clarification is required with
regard to the cellular mechanisms of regulation for AQP4 activity in the context of neurotrauma both
at an expression and protein level. It is reasonable to suggest that due to the conflicting evidence in
AQP4 protein/expression levels and the functional impact of such, the effect of AQP4 is mediated by
its subcellular localization within the cells.
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3.3. AQP9 in SCI
Currently, there is only one study in rats that shows upregulation of AQP9 after SCI with
myelotomy reducing SCI-induced AQP9 and correlating with reduced edema and enhanced functional
recovery [130]. However, the study is confounded by the same changes in AQP4, expressed at greater
levels after SCI and, hence, it is difficult to tease out the actual contribution of AQP9 in edema
formation after SCI. Nonetheless, the study does show regulation of AQP9 after SCI and myelotomy
and, therefore, requires further study with specific AQP9 inhibitors to dissect out the contribution of
AQP9 to spinal cord edema after injury.
3.4. AQPs as a Clinical Target to Reduce Neurotraumatic Edema: Past, Present, and Future
The approach to tre ting SCI is complex one due to the highly variable ature of the condition.
Despite our increasing pathophysiological knowledge of SCI including the primary, secondary,
and tertiary damage mechanisms and their consequences, current therapeutic approaches remain
largely palliative. This includes pain relief, rehabilitating symptomatic consequences such as
muscle spasticity or bowel problems, and/or implementing methods of patient self-care for
symptoms [131,132]. While these are essential elements for therapy, a large niche remains in
that currently, very little can be done in the way of acute treatment to prevent or minimize the
impact of secondary injuries such as edema and encouraging CNS regeneration of damaged nerves.
Such therapeutics could minimize the need for existing palliative care, decrease the costs required to
treat SCI patients, and could provide a higher quality of life for patients going forward.
The realization that edema can be a secondary damage-causing consequence of the initial injury
is a relatively new one and, therefore, therapeutic interventions are few [115]. Currently, there is
no specific therapeutic agent able to alter the movement of water through AQPs except mercury,
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which inhibits passage of water by disorganizing the structure of a number of oxygen-containing
motifs and causes the collapse of the arginine region and physically restricts water flow [133]. The AQP
water channel pores are very small and allow them to specifically permit the passage of water while
restricting passage of larger molecules. As such, designing non-mercurial clinical agents able to
specifically block or alter the biochemistry of these pores is a great challenge. Furthermore, the high
structural conservation between members of the AQP family means that targeting specific isoforms is
difficult [134].
Many attempts have been made at altering the genetic expression of AQP proteins to observe
changes in structure and function of the CNS both physiologically and pathologically [119,135].
For example, altering protein expression is often relatively long-lasting in effect and, as discussed,
it appears as though the role of AQP4 in SCI pathogenesis is biphasic in its contribution to formation
and resolution of edema. Hence, knocking out AQP4 may be beneficial for preventing formation of
edema in the acute stages of SCI, but the AQP4 protein must then later continue be expressed to ensure
its physiological functions are maintained [136]. However, one recent study demonstrated in a mouse
model of juvenile traumatic brain injury (jTBI) that siRNA treatment transiently knocks down AQP4,
decreases brain edema, and improves cognitive outcomes for as long as two months post-injury [137].
However, the timescale over which the siRNA operates until it becomes degraded has not been
reported. While the use of siRNA as therapeutic interventions is extremely promising on a molecular
level, it remains limited in its clinical practicality due to a number of neurobiological hurdles in
therapeutic administration. These include the restrictions imposed by blood-CNS barriers, the stability
of the siRNA as biological molecules, and the variation in the genetics of individuals [138]. Given the
apparently biphasic nature and lack of current clarification over thresholds of timepoints by which
AQP4 plays its various role, perhaps shorter-term interventions are the key for future interventions.
Currently, the only drug used clinically in treatment following SCI is methylprednisolone (MD).
When it was first investigated, it was considered to be an inhibitor of lipid peroxidation and was,
therefore, considered to be beneficial following SCI by limiting secondary damage through this
mechanism [139]. However, it has since demonstrated very little therapeutic effect throughout clinical
trials with many arguing that any benefits of the drug do not outweigh the adverse effects reported
such as pneumonia and respiratory failure [140,141]. Furthermore, administration of MD following
contusion SCI appeared to increase the spinal cord water content alongside reducing the expression of
AQP4 [142]. This suggests that, despite the potential therapeutic benefits offered to SCI patients by
way of reducing lipid peroxidation, it may undo its own beneficial effect by enhancing the levels of
edema. However, the mechanism by which MD affects AQP4 is not known and, therefore, the results
observed may simply be just the correlation.
Another drug currently under investigation for the treatment of SCI edema is melatonin.
Two earlier experimental studies suggested that melatonin was beneficial for treating SCI due to
its apparent ability to reduce free radical damage and neutropil toxicity [143] and reduce lipid
peroxidation [144]. Later studies focusing on SCI edema showed that, by contrast to the use of MD,
melatonin treatment immediately following a clip compression SCI appears to significantly reduce
both spinal cord water content and AQP4 expression after 24, 48, and 72 h following the injury [145].
Furthermore, similar compression models treated with melatonin demonstrated significantly improved
scores on a number of behavioral tests including rearing open-plane field tests, Basso, Beattie and
Bresnahan (BBB) locomotor tests, and the inclined plane test [146–148]. However, the mechanisms by
which melatonin has this effect on edema and whether it is the effect of reducing edema that improves
behavioral outcomes are not yet known.
Some of the clues for pharmacologically treating cytotoxic edema acutely may still reside in
biochemical studies of AQP4 and its regulation. In the CNS, the activity of astrocytic AQP4 can
be regulated by both short-term and long-term mechanisms. Such short-term mechanisms include
the “gating” of activity, which is controlled by phosphorylation of serine residues. PKC-mediated
phosphorylation of Ser180 has been reported numerously to result in the inhibition of the AQP4
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channel [44,149]. However, no structural changes to the AQP4 or the orthogonal array organization
was observed following Ser180 phosphorylation [150]. Furthermore, studies have also demonstrated
that phosphorylation at Ser111 via CaMKII and PKG results in the increased activation of AQP4 in
cultured astrocytes [151]. However, the precise role and consequence of phosphorylation in AQP4
regulation remains unclear. Some evidence suggests that AQP4-transfected and V1a-transfected
oocytes have reduced water permeability in response to Vasopressin [152] while previous evidence
suggested that Vasopressin results in increased CaMKII activation in astrocytes [153], which should
lead to increased AQP4 activity. As such, the role of phosphorylation as a regulatory mechanism for
AQP4 activity in the CNS remains to be clarified as well as the conformational changes that occur to
result in ‘gating’.
Another short-term regulatory mechanism of interest in CNS astrocytes is that of AQP4
‘trafficking’, which is similar in principle to the trafficking of kidney AQP2 in response to Vasopressin.
Earlier studies in gastric cells demonstrated that AQP4 could be shown to be internalized and
subsequently recycled to the surface membrane in response to Histamine [154]. More recently, it has
been described in primary cortical astrocytes that tonicity changes in the local environment, which is
likely reflective of an injured state following CNS injury, results in reversible translocation of AQP4 to
and from the cell membrane. This trafficking was demonstrated to be the result of a Ca2+-Calmodulin
(CaM)-PKA signaling cascade leading to Ser276 phosphorylation of AQP4, which triggers vesicular
translocation between intracellular stores and the cell surface membrane [155]. Therefore, efforts to
transiently inhibit the translocation of AQP4 acutely following a primary injury may offer a resolution
for the prevention of cytotoxic edema while not affecting the protein levels required for clearance of
vasogenic edema at later stages. Avoiding the use of genetic modification, temporary pharmacological
inhibitors of these mechanisms would provide the ability to treat patients acutely and, for a period of
time, required to delay the onset of cytotoxic edema until the local injury environment resolves and no
longer promotes it.
4. Conclusions
This review highlights some of the current findings about AQPs and their regulation after
SCI. It is evident that AQP1, 4 and 9 play a major role in water regulation in the spinal cord
but differential expression of AQPs in different cell types suggests multiple functions that require
greater understanding prior to the development of therapies aimed at reducing SCI-induced edema.
For example, it is evident that AQP4 is probably the most important molecule in regulating water in the
spinal cord. However, knockout mouse studies have suggested that complete deletion of AQP4 while
reducing acute edema and improving functional outcomes may be detrimental in the chronic stages
where AQP4 is required for the clearance of water. Hypoxia and hypertonicity clearly regulate different
AQPs and, therefore, may be important mediators of AQP function. Hence, greater understanding of
the biology of AQPs after SCI will lead to more effective treatments for SCI-induced edema and relief
from the secondary detrimental effect.
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